Upstream Bio’s verekitug meets endpoints in Phase 2 rhinosinusitis trial

Upstream Bio (UPB) announced positive top-line results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps, or CRSwNP. Verekitug is the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin, or TSLP. Over the 24-week treatment period, verekitug, dosed 100mg every 12 weeks, met the primary endpoint and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in both endoscopic nasal polyp score and nasal congestion score, with a generally well tolerated safety profile consistent with previous studies. Treatment with verekitug also resulted in a significant reduction in the need for surgery or systemic corticosteroids. Significant improvements were also observed in other key secondary endpoints. Verekitug was generally well tolerated, demonstrating a favorable safety profile consistent with previous studies, with no SAEs observed. The company plans to further engage with global regulatory authorities on the continued development of verekitug.